Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Below are highlights of recent Brain Tumor Program research.
St. Jude Children’s Research Hospital-Washington University Pediatric Cancer Genome Project offers new leads to improved outcomes for children with high-grade glioma brain tumors; particularly youngest patients. (Suzanne Baker, PhD, and Jinghui Zhang, PhD)
St. Jude Children’s Research Hospital -Washington University Pediatric Cancer Genome Project identifies the most common genetic alteration yet in the brain tumor ependymoma; results offer clues for fighting other cancers. (Richard Gilbertson, MD, PhD, David Ellison, MD, PhD, Jinghui Zhang, PhD)
The St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project advances understanding of genetic defects underlying childhood low-grade gliomas and identifies promising new drug therapies. (Dr. David Ellison)
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project lifts lid on the most aggressive subtype of medulloblastoma and finds genes that cooperate in tumor development. (Dr. Richard Gilbertson)
St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project provides first evidence linking cancer to mutations in genes involved in DNA organization. (Dr. Suzanne Baker)
Study led by St. Jude Children’s Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.
St. Jude Children’s Research Hospital investigators use a novel model system to show how specific mutations can induce glioma formation in multiple regions of the brain and to begin studying patient response to a new generation of targeted therapies.
International effort led by St. Jude Children’s Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers
Scientists have long recognized that cancers may look the same under the microscope, but carry different mutations, respond differently to treatment and result in vastly different outcomes for patients.
Researchers from St. Jude Children’s Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented today at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor.
The most comprehensive analysis yet of the genetic imbalances at the heart of childhood brain tumors known as high-grade gliomas (HGGs) identified a cancer gene that is unusually active in some tumors and is now the focus of a St. Jude Children’s Research Hospital clinical trial.
St. Jude Children’s Research Hospital and Washington University School of Medicine in St. Louis, today announced an unprecedented effort to identify the genetic changes that give rise to some of the world’s deadliest childhood cancers. The team has joined forces to decode the genomes of more than 600 childhood cancer patients who have contributed tumor samples for this historic effort.
St. Jude scientists’ findings in ataxia telangiectasia-like disease and Nijmegen breakage syndrome offer insight into the links between brain disease and cancer vulnerability in people carrying the diseases.